MedTrace Logo

Study of CM310 in Healthy Subjects

NCT06161090 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 33

Last updated 2023-12-07

No results posted yet for this study

Summary

This is a single center, randomized, double-blind, placebo-controlled, dose escalation study.

Conditions

  • Healthy

Interventions

BIOLOGICAL

CM310

CM310 injection

DRUG

Placebo

subcutaneous injection

Sponsors & Collaborators

  • Keymed Biosciences Co.Ltd

    lead INDUSTRY

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2019-09-03
Primary Completion
2020-01-13
Completion
2020-01-13

Countries

  • China

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06161090 on ClinicalTrials.gov